The territories of Czech Republic, Slovakia, and Poland, have a combined cervical cancer addressable screening population of over 17.91 million women, presenting a significant market opportunity for the Company.
Asprionix is a well-established specialised medical device distributor based in Prague, with a rapidly growing turnover and increasing presence in central and eastern Europe.
Together with Aspironix, the Company will develop a comprehensive market access plan and have begun preliminary Key Opinion Leaders (KOL) engagement for the region.
Truscreen CEO, Victoria Potarina, said “The distribution agreement with Aspironix will enable us to significantly expand our distribution capabilities in central and eastern Europe, bringing Truscreen’s latest real-time cervical cancer screening technology to the women of Czech Republic, Slovakia and Poland.
The rationalisation of our distributor portfolio will see established and committed medical device distributors, like Aspironix partnering with Truscreen to bring our Truscreen cervical cancer screening technology to the millions of women who are currently not covered by effective cervical cancer screening.”